69888-88-6

Basic information

• Product Name: 2,5-Pyrrolidinedione, 1-[[(9Z,12Z)-1-oxo-9,12-octadecadienyl]oxy]-
• CAS NO: 69888-88-6
• Molecular Formula: C22H35NO4
• Molecular Weight: 377.524
• Mol File: 69888-88-6.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 2,5-Pyrrolidinedione, 1-[[(9Z,12Z)-1-oxo-9,12-octadecadienyl]oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-Pyrrolidinedione, 1-[[(9Z,12Z)-1-oxo-9,12-octadecadienyl]oxy]-(69888-88-6)
• EPA Substance Registry System: 2,5-Pyrrolidinedione, 1-[[(9Z,12Z)-1-oxo-9,12-octadecadienyl]oxy]-(69888-88-6)

Safety Data

• Hazardous Substances Data: 69888-88-6(Hazardous Substances Data)

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 60-33-3 linoleic acid 

Downstream Products

• 2764-03-6 N-linoleoyl-glycine 

Relevant articles and documents

The effect of unsaturation on the formation of self-assembled gels from fatty acid L-serine amides and their cytotoxicity towards caco-2 cancer cells

A series of saturated and unsaturated fatty acid l-serines 3 were synthesized and their ability to form self-assembled gels was investigated. The saturated (lauroyl 3a and steraoyl 3b) and monounsaturated (oleoyl 3c) fatty acid l-serines form gels in both water and organic solvent, whereas the diunsaturated linoleyl-l-serine 3d does not form gels in these solvents, indicating that unsaturation adversely affects the gelation process. Cytotoxicity studies on these compounds with Caco-2 cancer cells in vitro show that these gels are only moderately cytotoxic at concentrations up to 0.5 mM, making them a promising candidate for applications such as drug delivery. CSIRO 2009.

CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY

Nanoparticle compositions for delivery of nucleic acids to subjects including carriers comprising polyester (PE) dendrimers or dendrons, and therapeutic or immunogenic nucleic acid agents enclosed within the PE are described. Methods for treating or preve

PERSONAL CARE COMPOSITIONS COMPRISING FATTY ACID AMIDE DERIVATIVES

In one embodiment, the present invention provides a personal care composition, comprising: (i) a compound of Formula (1) at a concentration from 0.0001 wt % to 20 wt % of the composition; wherein R is selected from the group consisting of C15-C23 conjugated dienes, C15-C23 hydroxylated mono unsaturated alkenes, and C15-C23 hydroxylated alkanes; wherein R1 is selected from the group consisting of H, C1-C4 alkyl, - CH2OH, -CH2(CH3)-OH,-[CH2]4-NH2, -CH2-CO2H, -[CH2]2-CO2H, (I), (II) and (III); wherein R3 is -CO2H; -CH2CO2H; -CH2CH2CO2H;; and (ii) a cosmetically acceptable carrier.